Annex to C. SCIT 2505

Country **SWEDEN**

QUESTIONNAIRE

ON THE GRANT AND PUBLICATION OF "SUPPLEMENTARY PROTECTION CERTIFICATES" FOR MEDICINAL AND PHYTOPHARMACEUTICAL PRODUCTS OR EQUIVALENT INDUSTRIAL PROPERTY RIGHTS *(SPCs)*

Important Remarks

1. The survey published in 1997 concerned only "Supplementary Protection Certificates" for medicinal products or equivalent industrial property titles of protection, but not the "Supplementary Protection Certificates" for phytopharmaceutical products.

2. This questionnaire aims at updating the 1997 survey and at including the industrial property titles of protection for phytopharmaceutical products.

3. In order to facilitate the updating of the said survey and the inclusion of information on phytopharmaceutical products, appropriate entries have been added. For the purposes of the survey, medicinal products and phytopharmaceutical products are both covered by the abbreviation "SPCs."

4. The survey will be made available through the WIPO Web site and will be kept up to date. For this purpose, you are kindly requested to inform the International Bureau of any change in the applicable legislation in your country.

5. Offices not covered by the previous survey are kindly requested to provide information as available.

6. If your Office participated in the previous survey and there are no changes, please indicate "no change."

7. Please, refer to Part 7.2.1 of the WIPO "Handbook on Industrial Property Information and Documentation" when responding to the following questions:

Question 1: **Does your Office grant "supplementary protection certificates" for medicinal products or equivalent industrial property rights (SPCs) that extend the validity of patents covering medicinal, pharmaceutical, agrochemical or cognate products and phytopharmaceutical products?**

(a) In the field of medicinal products

Yes ☐

No ☐

(b) In the field of phytopharmaceutical products

Yes ☐

No ☐

Question 2: **Will your Office start granting SPCs in the future?**

(a) In the field of medicinal products

Yes ☐

No ☐

(b) In the field of phytopharmaceutical products

Yes ☐

No ☐

Question 3: **Please, specify the legal basis for granting SPCs (national law, regional regulation, etc.).**

(a) In the field of medicinal products

(1) Laws

(2) Decrees, ordinances

(3) Other Regulation (EC) No 1768/92

(b) In the field of phytopharmaceutical products

(1) Laws

(2) Decrees, ordinances

(3) Other Regulation (EC) No 1610/96

Question 4: Please specify the name of the SPC granted by your Office.

(a) In the field of medicinal products

(b) In the field of phytopharmaceutical products

(a) Tilläggsskydd för läkemedel

(b) Tilläggsskydd för växtskyddsmedel

Question 5: Please specify for which fields of technology or which products an SPC can be obtained (for example, medicinal products, phytopharmaceutical products, herbicides, agro-chemicals, all products subject to regulatory approval for marketing, etc.).

Medicinal products and phytopharmaceutical products (plant protection products)

Question 6: Does your Office publish or intend to publish the receipt of an application for an SPC?

(If "Yes," please attach specimen of a front page of an SPC and/or of announcements regarding SPCs made in an Official Gazette.)

(a) In the field of medicinal products

Yes ☐

No ☐

(b) In the field of phytopharmaceutical products

Yes Y

No □

Question 7: **If your reply to question 6 is "Yes," please indicate the minimum elements a publication must contain:**

(a) In the field of medicinal products

(i) number alloted to receipt of the application

(ii) date of said receipt

(iii) name and address of the applicant

(iv) number of the basic patent

(v) title of the invention

(vi) number of any authorization to place the product on the market, including the product identified in that authorization

(vii) date of the said authorization

(viii) other elements (please specify)

where relevant, the number and date of the first authorization to place the product on the market in the EEA

(b) In the field of phytopharmaceutical products

(i) number alloted to receipt of the application

(ii) date of said receipt

(iii) name and address of the applicant

(iv) number of the basic patent

(v) title of the invention

(vi) number of any authorization to place the product on the market, including the product identified in that authorization

(vii) date of the said authorization

(viii) other elements (please specify)

where relevant, the number and date of the first authorization to place the product on the market in the EEA

Question 8: Does your Office publish or intend to publish the fact that an SPC has been granted?

(If "Yes," please attach specimen of a front page of an SPC and/or of announcements regarding the grant of SPCs made in an Official Gazette.)

(a) In the field of medicinal products Yes

(b) In the field of phytopharmaceutical products Yes

Question 9: If your reply to question 8 is "Yes," please indicate the minimum elements a publication must contain:

(a) In the field of medicinal products

(i) registration number allotted to the granted SPC

(ii) date of registration of the granted SPC

(iii) name and address of the holder of the SPC

(iv) number of the basic patent

(v) title of the invention

(vi) number of any authorization to place the product on the market, including the product identified in that authorization

(vii) date of the said authorization

(viii) duration of the SPC

(ix) other elements, e.g., patent classification, product name (please specify):

where relevant, the number and date of the first authorization to place the product on the market in the EEA

(b) In the field of phytopharmaceutical products

(i) registration number allotted to the granted SPC

(ii) date of registration of the granted SPC

(iii) name and address of the holder of the SPC

(iv) number of the basic patent

(v) title of the invention

(vi) number of any authorization to place the product on the market, including the product identified in that authorization

(vii) date of the said authorization

(viii) duration of the SPC

(ix) other elements, e.g., patent classification, product name (please specify):

where relevant, the number and date of the first authorization to place the product on the market in the EEA

Question 10: In which form does your Office make or intend to make the publications referred to in questions 6 and 8?

(a) In the field of medicinal products

(i) As regards applications for SPCs

(a) as part of an Official Gazette?

(b) by publishing the application?

(c) by laying the application open to public inspection?

(d) through online databases (or the Office's Web site)?

(e) by copy delivery of the application on request?

(ii) As regards granted SPCs

(a) as part of an Official Gazette?

(b) by publishing the SPC?

(c) by laying the SPC open to public inspection?

(d) through online databases (or the Office's Web site)?

(e) by copy delivery of the SPC on request?

(b) In the field of phytopharmaceutical products

(i) As regards applications for SPCs

(a) as part of an Official Gazette?

(b) by publishing the application?

(c) by laying the application open to public inspection?

(d) through online databases (or the Office's Web site)?

(e) by copy delivery of the application on request?

(ii) As regards granted SPCs

(a) as part of an Official Gazette?

(b) by publishing the SPC?

(c) by laying the SPC open to public inspection?

(d) through online databases (or the Office's Web site)?

(e) by copy delivery of the SPC on request?

Question 11: **If your Office enters or intends to enter data from the documents relating to SPCs in online databases (internal or commercial ones), please indicate the names(s) of the databases(s) and specify the bibliographic data elements:**

(a) In the field of medicinal products

(i) name(s) of database(s)

(ii) bibliographic data elements

(b) In the field of phytopharmaceutical products

(i) name(s) of database(s)

(ii) bibliographic data elements

Question 12: **If your Office allots or intends to allot specific application and/or registration numbers to SPCs, please give details:**

(a) As regards medicinal products

(i) concerning the numbering system for applications for SPCs

(ii) concerning the numbering system for registrations or grants of SPCs (if different from (a)(i))

(b) As regards phytopharmaceutical products

(i) concerning numbering system for applications for SPCs

(ii) concerning the numbering system for registrations or grants of SPCs (if different from (b)(i))

(a) and (b) The same numbering systems for applications and grants of SPC

A special number is given to SPC consisting of seven digits and a check-up digit. First the two last digits of the year, the digit 9 indicating the SPC and then four digits indicating the number in chronological order. For example O090004-3, namely the fourth SPC application in year 2000 where the "-3" is the checkdigit.

Contact details:

(a) Name: Ingela Söderlund

(b) Title: Legal adviser

(c) Office/Organization: The Swedish Patent- and Registration Office

(d) E-mail prv@prv.se

(e) Facsimile: 08-666 02 86

(f) Telephone: 08-782 25 81

[End of Questionnaire]

PRV

PATENT- OCH REGISTRERINGSVERKET

The Swedish certificate

EG-FÖRORDNINGEN 1768/92

BEVIS OM TILLÄGGSSKYDD 9990029-2

Meddelat 1999-12-20

I enlighet med artikel 10.1 i ovanstående förordning meddelas tilläggsskydd på produkten Becaplermin (rekombinant human blodplättshärledd tillväxtfaktor-BB, rh PDGF-BB).

Produkten skyddas av grundpatentet EP 85112852.0 (0177957)

Innehavare av tilläggsskyddet

ZymoGenetics, Inc

Tilläggsskyddet inträder from 2005-10-11

och kan upprätthållas t o m 2010-10-10

För varje påbörjat avgiftsår skall en årsavgift betalas för tilläggsskyddet.

Första årsavgiften förfaller till betalning 2005-10-31

I tjänsten

Gerd Strandell

Ansökan om tilläggsskydd för läkemedel

A61K 31/165 ---> (51) C07C 311/02

A61K 31/395 ---> (51) C07C 311/02

C07C 211/45 ---> (51) C07C 311/02

C07C 215/42 ---> (51) C07C 311/02

C07C 217/64 ---> (51) C07C 311/02

C07C 233/64 ---> (51) C07C 311/02

C07C 237/28 ---> (51) C07C 311/02

---

(51) C07C 311/02 (21) 0090007-6 L
C07C 311/15 C07C 317/14
C07D 295/18 C07C 233/64
C07C 237/28 C07C 215/42
C07C 217/64 C07C 211/45
A61K 31/165 A61K 31/395
(21) 87303782.4 (11) 0 245 997
(92) 1999-11-29 EG EU/1/99/121/001
(93) 1999-11-29 EG EU/1/99/121/001
(95) Dofetilide, eventuellt i form av ett farmaceutiskt föredraget salt
(54) N-substituerade P-aminoetylsulfonanilider som antiarytmika samt mellanprodukter för dessa
(71) Pfizer Limited, Sandwich Kent CT13 9NJ,

C07C 311/15 ---> (51) C07C 311/02

C07C 317/14 ---> (51) C07C 311/02

C07D 295/18 ---> (51) C07C 311/02
